Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer
1998

Study of Irinotecan and Cisplatin with Radiotherapy for Lung Cancer

Sample size: 12 publication Evidence: low

Author Information

Author(s): A Yokoyama, Y Kurita, N Saijo, T Tamura, K Noda, K Shimokata, T Matsuda

Primary Institution: Niigata Cancer Center Hospital

Hypothesis

Can irinotecan and cisplatin combined with radiotherapy improve outcomes for patients with unresectable stage III non-small-cell lung cancer?

Conclusion

The combination of irinotecan and cisplatin with concurrent radiotherapy was found to be unacceptable due to high toxicity and low treatment completion rates.

Supporting Evidence

  • Four of six patients at level 1 completed the treatment.
  • An overall response rate of 67% was observed.
  • Leucopenia was the principal myelotoxic adverse effect.

Takeaway

Doctors wanted to see if a new cancer treatment could help patients with a tough type of lung cancer, but it turned out to be too hard on their bodies.

Methodology

Patients received three courses of chemotherapy with irinotecan and cisplatin, followed by radiation therapy over six weeks.

Limitations

The study was discontinued due to unacceptable toxicity and low dose intensity.

Participant Demographics

{"age":{"median":58,"range":"35-68"},"sex":{"male":9,"female":3},"performance_status":{"0":3,"1":9},"cell_type":{"adenocarcinoma":7,"squamous":4,"large_cell":1},"clinical_stage":{"IIIA":2,"IIIB":10}}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication